NASEM: Reduce cancer drug waste by reformulating development, payments, dosing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Once an expensive cancer drug is discarded, it’s not worth it for drug developers, health care providers, and payers to recoup its cost, the National Academies of Sciences, Engineering, and Medicine said in a congressionally mandated report.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Alexandria Carolan
Alexandria Carolan
Reporter

Login